News & Updates
Filter by Specialty:
Sitra + nivo slightly better than docetaxel in advanced NSCLC
05 Feb 2024
Treatment with sitravatinib plus nivolumab (sitra + nivo) results in numerically longer median overall survival (OS), albeit statistically nonsignificant, in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC) compared with docetaxel, a study has shown.
Sitra + nivo slightly better than docetaxel in advanced NSCLC
05 Feb 2024Sacituzumab govitecan makes case as third-line therapy in mTNBC
05 Feb 2024
Third-line treatment with sacituzumab govitecan works better than the physician’s treatment of choice in metastatic triple-negative breast cancer (mTNBC), an invasive histologic subtype with a poor prognosis and rapid progression, as shown in a recent study.